Mipomersen, an antisense oligonucleotide inhibitor of APOB synthesis, is approved by the U. S. Food and Drug Administration as an orphan drug for use in familial hypercholesterolemia (60). This evidence concerns the gene APOB and familial hypercholesterolemia.